Search

Displaying results 2221 - 2230 of 3020 in total
  1. Drug

    Pimavanserin

    go.drugbank.com/drugs/DB05316
    ApprovedInvestigational

    [L48241,A232573] Pimavanserin was also under review as a potential treatment for dementia-related psychosis; however, as of April 2021, FDA approval has not been granted for this indication despite previous … [A232783] It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis thanks to favorable results from a pivotal six-week, randomized

  2. Drug

    Tezacaftor

    go.drugbank.com/drugs/DB11712
    ApprovedInvestigational

    [L1595] It was developed by Vertex Pharmaceuticals and FDA approved in combination with [ivacaftor] to manage cystic fibrosis.[L6814] This drug was approved by the FDA on February 12, 2018.

  3. Drug

    Morniflumate

    go.drugbank.com/drugs/DB09285
    Investigational

    Morniflumate is a non-steroidal anti-inflammatory drug with antipyretic properties. It is the morpholinoethyl ester of niflumic acid . In one study, post morniflumate ingestion, physical examination and clinical symptoms of those with br...

  4. Drug

    Heparin

    go.drugbank.com/drugs/DB01109
    ApprovedInvestigational

    Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibl...

    Mixtures: BARICUS 50 IU/%1/%10 JEL , 50 G, HEPARINISED SALINE INJECTION 10 iu/mlProducts: HEPARIN NA BRA 25000IE, HEPARIN NA BRA 25000IE IIL
  5. Drug

    Ripretinib

    go.drugbank.com/drugs/DB14840
    ApprovedInvestigational

    Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020.

  6. Drug

    Donanemab

    go.drugbank.com/drugs/DB16647
    ApprovedInvestigational

    [A232214] On July 2, 2024, donanemab was approved by the FDA for the treatment of AD in patients with mild cognitive impairment or dementia symptoms.

  7. Drug

    Teduglutide

    go.drugbank.com/drugs/DB08900
    ApprovedInvestigational

    FDA approved on December 21, 2012.

  8. Drug

    Mirdametinib

    go.drugbank.com/drugs/DB07101
    ApprovedInvestigational

    On February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1).

  9. Drug

    Protirelin

    go.drugbank.com/drugs/DB09421
    Approved

    Although not currently available in any FDA-approved product, protirelin is a component of the TRH Test where it is used to test the response of the anterior pituitary gland in conditions such as secondary

  10. Drug

    Butamben

    go.drugbank.com/drugs/DB11148
    ApprovedWithdrawn

    The FDA removed all parenteral butamben products from the market, possibly due to the poor solubility of this drug.[A254247,L43942]